A
A. Jon Stoessl
Researcher at University of British Columbia
Publications - 212
Citations - 19006
A. Jon Stoessl is an academic researcher from University of British Columbia. The author has contributed to research in topics: Parkinson's disease & Dopamine. The author has an hindex of 54, co-authored 206 publications receiving 17165 citations. Previous affiliations of A. Jon Stoessl include TRIUMF & Lawson Health Research Institute.
Papers
More filters
Journal ArticleDOI
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Alexander Zimprich,Alexander Zimprich,Saskia Biskup,Petra Leitner,Peter Lichtner,Matthew J. Farrer,Sarah Lincoln,Jennifer M. Kachergus,Mary M. Hulihan,Ryan J. Uitti,Donald B. Calne,A. Jon Stoessl,Ronald F. Pfeiffer,Nadja Patenge,Iria Carballo Carbajal,Peter Vieregge,Friedrich Asmus,Bertram Müller-Myhsok,Dennis W. Dickson,Thomas Meitinger,Tim M. Strom,Zbigniew K. Wszolek,Thomas Gasser +22 more
TL;DR: High-resolution recombination mapping and candidate gene sequencing in 46 families found six disease-segregating mutations in a gene encoding a large, multifunctional protein, LRRK2 (leucine-rich repeat kinase 2), which may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism.
Journal ArticleDOI
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease†
C. Warren Olanow,Christopher G. Goetz,Jeffrey H. Kordower,A. Jon Stoessl,Vesna Sossi,Mitchell F. Brin,Kathleen M. Shannon,G. Michael Nauert,Daniel P. Perl,James Godbold,Thomas B. Freeman +10 more
TL;DR: Fetal nigral transplantation currently cannot be recommended as a therapy for PD based on results, and Stratification based on disease severity showed a treatment effect in milder patients.
Journal ArticleDOI
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.
Anthony E. Lang,Steven S. Gill,Nik K. Patel,Andres M. Lozano,John G. Nutt,Richard D. Penn,David J. Brooks,Gary Hotton,Elena Moro,Peter Heywood,Matthew Brodsky,Kim J. Burchiel,Patrick J. Kelly,Arif Dalvi,Burton L. Scott,Mark Stacy,Dennis A. Turner,V. G. Frederich Wooten,W. J. Elias,Edward R. Laws,Vijay Dhawan,A. Jon Stoessl,James Matcham,Robert J. Coffey,Michael Traub +24 more
TL;DR: This randomized controlled clinical trial was designed to confirm initial clinical benefits observed in a small, open‐label trial using intraputamenal (Ipu) infusion of recombinant human GDNF (liatermin).
Journal ArticleDOI
Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson's Disease
Raúl de la Fuente-Fernández,Thomas J. Ruth,Vesna Sossi,Michael Schulzer,Donald B. Calne,A. Jon Stoessl +5 more
TL;DR: In vivo evidence is provided for substantial release of endogenous dopamine in the striatum of PD patients in response to placebo, indicating that the placebo effect in PD is powerful and is mediated through activation of the damaged nigrostriatal dopamine system.
Journal ArticleDOI
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
Alan L Whone,Ray L. Watts,A. Jon Stoessl,Margaret R. Davis,Sven N. Reske,Claude Nahmias,Anthony E. Lang,Olivier Rascol,Maria J Ribeiro,Philippe Remy,Werner Poewe,Robert A. Hauser,David J. Brooks +12 more
TL;DR: Ropinirole is associated with slower progression of PD than levodopa as assessed by 18F‐dopa PET, and this prospective, 2‐year, randomized, double‐blind, multinational study compared the rates of loss of dopamine‐terminal function in de novo patients with clinical and 18F-dopaPET evidence of early PD.